NASDAQ:ZLAB 延时15分钟

成交量

Ying Du: Ying Du is the founder of Hutchison MediPharma Ltd. (2002, Chief Executive Officer), Zai Lab Ltd. (2014, Chairman & Chief Executive Officer), and Zai Venture Partners (2017, General Partner). Dr. Du is currently a Director at Eden Biologics, Inc. (2012 - present). Former positions include Chief Scientific Officer at HUTCHMED (China) Ltd., Executive Vice President-Healthcare Investment at Hutchison Whampoa (China) Ltd., and Venture Partner at Wuhan HongShan Huanxia Technology Co., Ltd. Education includes a doctorate from the University of Cincinnati (Ohio, 1994) and an undergraduate degree from Jilin University (1987).

Jonathan Wang: Jonathan Wang is currently the Chief Business Officer at Zai Lab Ltd. and a Senior Associate at Ally Bridge Group HK Ltd. He previously worked as a Consultant at KPMG Hong Kong and as an Investment Manager at Navis Management Sdn. Bhd. Mr. Wang graduated from the University of Hong Kong in 2013, The Hong Kong Polytechnic University in 2010, and The Wharton School of the University of Pennsylvania with an MBA.

Ning Xu: Ning Xu is currently the Executive VP & Head-Clinical Operations at Zai Lab Ltd. Prior to this, he worked as the Director at Drug Information Association and as the Vice President & Head-Clinical Development Service at Fortrea Pharmaceutical Research & Development (Beijing) Co. Dr. Xu received his graduate degree from the University of Illinois in 2000 and his undergraduate degree from Peking Union Medical College in 1991.

Frazor Titus Edmondson: Frazor Titus Edmondson currently works at Zai Lab Ltd., as Secretary & Chief Legal Officer from 2025. Mr. Edmondson also formerly worked at Sumitomo Pharma America, Inc., as Secretary, Associate General Counsel & VP and Biogen, Inc., as Chief Corporation Counsel & Senior Vice President from 2014 to 2020. Mr. Edmondson received his undergraduate degree in 1988 from Washington & Lee University and graduate degree in 1993 from Widener University School of Law.

James Yan: James Yan is currently the Chief Operating Officer-Research & Development at Zai Lab Ltd. and is also a member of the Chinese Society of Toxicology. Previously, he worked as the Head-Drug Safety Evaluation at Hutchison MediPharma Ltd. from 2009 to 2011. He holds a doctorate degree from Peking Union Medical College.

Ann E. Beasley: Ann E. Beasley is currently the Chief Compliance Officer at Zai Lab Ltd. She previously worked as the Chief Compliance Officer & Senior Vice President at Biogen, Inc. Ms. Beasley has a graduate degree from Northeastern University School of Law and an undergraduate degree from The University of Tulsa College of Law.

Joshua L. Smiley: Joshua L. Smiley currently works at Eskenazi Health Foundation, as Director, Butler University, as Trustee, Zai Lab Ltd., as Co-President & Chief Operating Officer from 2023, and Unseen Capital LLC, as Advisor. Mr. Smiley also formerly worked at CoLucid Pharmaceuticals, Inc., as Treasurer, Director & Vice President, Gilead Connecticut, Inc., as Director, Elanco Animal Health, Inc., as Director from 2018 to 2019, Eli Lilly & Co., as Chief Financial Officer & Senior Vice President from 2018 to 2021, and Lilly Research Laboratories, as Chief Financial Officer, Controller & SVP-Finance from 2011 to 2015. Mr. Smiley received his undergraduate degree in 1993 from Harvard University.

Peter Huang: Peter Huang is currently the Chief Scientific Officer at Zai Lab Ltd. Prior to this, he worked at Zentalis Pharmaceuticals, Inc. as the Senior Vice President-Discovery Research from 2015 to 2022. He obtained a doctorate degree from Iowa State University.

Rafael G. Amado: Rafael G. Amado currently works at Zai Lab Ltd., as Co-President, Head-Global Research & Development from 2024. Dr. Amado also formerly worked at Amgen Ltd., as Executive Director-Therapeutic Oncology from 2003 to 2008, Poseida Therapeutics, Inc., as Independent Director from 2023 to 2025, GSK Plc, as Senior Vice President from 2013 to 2015, the University of California, Los Angeles, as Assistant Clinical Professor, Adaptimmune LLC, as Chief Medical Officer & Vice President-R&D from 2018 to 2019, Adaptimmune Therapeutics Plc, as President-Research & Development from 2018 to 2019, and Allogene Therapeutics, Inc., as Chief Medical Officer, EVP-Research & Development from 2019 to 2022. Dr. Amado received his doctorate degree in 2003 from the University of Seville.

Lina Zhang: Lina Zhang currently works as the VP-Corporate Strategy & Capital Markets at Zai Lab Ltd.

Ya jing Chen: Ya jing Chen currently works at Zai Lab Ltd., as Chief Financial Officer from 2023. Dr. Chen received her Masters Business Admin degree from The Trustees of Columbia University in The City of New York and doctorate degree from New York University.

Christine K. Chiou: Christine K. Chiou is currently the Senior Vice President & Head-Investor Relations at Zai Lab Ltd. Prior to her current position, she worked as the Head-Investor Relations at Incyte Corp. from 2019 to 2023. She also held the position of Principal at Merck & Co., Inc., Research Analyst at Daiichi Sankyo, Inc., and Investor Relations Contact at Allergan Ltd. (Ireland). Additionally, she worked as an Assistant Vice President & Equity Analyst at Barclays Capital, Inc. from 2011 to 2013. Ms. Chiou obtained an MBA from The Trustees of Columbia University in The City of New York in 2009 and completed her undergraduate studies at Bryn Mawr College.

Jim Massey: Jim Massey currently works at Zai Lab Ltd., as Chief Sustainability Officer from 2021.

Robert J. Brown: Robert J. Brown currently works at Zai Lab Ltd., as Chief Medical Officer-Oncology from 2023. Dr. Brown also formerly worked at Nurix Therapeutics, Inc., as Senior Vice President-Clinical Development from 2021 to 2023. Dr. Brown received his undergraduate degree from Massachusetts Institute of Technology and doctorate degree from Weill Cornell Medical College.

Zhu Tong: Zhu Tong is currently working as the Chief Commercial Officer at Zai Lab Ltd.

再鼎医药